Methylphenidate is a central nervous system (CNS) stimulant, most often used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It has many trade names, the most well-known being Ritalin.
Evidence[edit | edit source]
Methylphenidate has been used with success in a subset of ME/CFS patients. In 2016, Blockmans, et al, concluded that use of methylphenidate by CFS patients with concentration difficulties had a positive effect in about one out of three clinical trial patients.
Dr. Jon Kaiser is performing clinical trials on a pharmaceutical product which he developed called Synergy (KPAX002) that is a combination of a low dosage of methylphenidate hydrochloride and over-the-counter mitochondrial support nutrients. The phase II study concluded that 36% of the patients taking the Synergy treatment had a >20% reduction in overall ME/CFS symptoms after 28 days.
Notable studies[edit | edit source]
- 2015, A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome.(Full Text)
- 2018, KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial(Full Text)
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Kaiser, JD (Jul 15, 2015), "A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome", International Journal of Clinical and Experimental Medicine, 8 (7): 11064–11074, PMID 26379906
- Blockmans, Daniel; Persoons, Philippe (Jun 27, 2016). "Long-term methylphenidate intake in chronic fatigue syndrome". Acta Clinica Belgica. 71 (6): 407–414. doi:10.1080/17843286.2016.1200816. ISSN 1784-3286.
- Montoya, Jose G; Anderson, Jill N; Adolphs, Danya L; Bateman, Lucinda; Klimas, Nancy; Levine, Susan M; Garvert, Donn W; Kaiser, Jon D (2018), "KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial" (PDF), International Journal of Clinical and Experimental Medicine, 11 (3): 2890-2900
central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.
mitochondria - Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.
phase two - A trial involve patients to assess side effects and effectiveness for a particular clinical condition. Typically 100-300 patients.